Trial Profile

A single compassionate use study of troculeucel in patient with mild-stage Alzheimer's disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jul 2025 New trial record
10 Jul 2025 According to a NKGen Biotech media release, this exploratory work is being conducted in collaboration with Anita Fletcher
10 Jul 2025 According to a NKGen Biotech media release, the company announced the administration of the first dose of troculeucel under a single compassionate use, Investigational New Drug authorization cleared by the U.S. Food and Drug Administration to a patient with mild-stage Alzheimer's disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com